Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $1.7 million.

  • Adma Biologics' Interest Expenses fell 5212.92% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year decrease of 5156.38%. This contributed to the annual value of $13.9 million for FY2024, which is 4434.01% down from last year.
  • As of Q3 2025, Adma Biologics' Interest Expenses stood at $1.7 million, which was down 5212.92% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Interest Expenses registered a high of $6.4 million during Q3 2023, and its lowest value of $1.7 million during Q3 2025.
  • Its 5-year average for Interest Expenses is $4.0 million, with a median of $3.5 million in 2024.
  • In the last 5 years, Adma Biologics' Interest Expenses soared by 8043.47% in 2023 and then tumbled by 5367.66% in 2024.
  • Quarter analysis of 5 years shows Adma Biologics' Interest Expenses stood at $3.3 million in 2021, then surged by 73.0% to $5.7 million in 2022, then rose by 8.34% to $6.2 million in 2023, then tumbled by 53.68% to $2.9 million in 2024, then crashed by 41.82% to $1.7 million in 2025.
  • Its Interest Expenses stands at $1.7 million for Q3 2025, versus $1.8 million for Q2 2025 and $2.0 million for Q1 2025.